Amonafide

Amonafide

Clinical data
Trade names	Xanafide, Quinamed
ATC code	none
Identifiers
IUPAC name 5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
CAS Number	69408-81-7
PubChem CID	50515
ChemSpider	45804  Y
UNII	1Q8D39N37L
KEGG	D10090  Y
ChEMBL	ChEMBL428676  Y
CompTox Dashboard (EPA)	DTXSID30219562
Chemical and physical data
Formula	C16H17N3O2
Molar mass	283.331 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
InChI InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 Y Key:UPALIKSFLSVKIS-UHFFFAOYSA-N Y
(verify)

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator. ^{[1] [2]}

It was being developed as an anti-cancer therapy by Antisoma. ^[3]

As of 2008 ^[update] , it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML). ^[4] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.^{[ citation needed ]}

See also

• Alrestatin

References

1. Allen SL, Lundberg AS (July 2011). "Amonafide: a potential role in treating acute myeloid leukemia". Expert Opinion on Investigational Drugs. 20 (7): 995–1003. doi:10.1517/13543784.2011.585756. PMID   21591994. S2CID   10999582.
2. Freeman CL, Swords R, Giles FJ (February 2012). "Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?". Expert Review of Hematology. 5 (1): 17–26. doi:10.1586/ehm.11.68. PMID   22272701. S2CID   26740617.
3. "Antisoma's Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial". Genetic Engineering & Biotechnology News. 29 March 2010. Archived from the original on 1 April 2010.
4. Clinical trial number NCT00715637 for "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study" at ClinicalTrials.gov

External links

• Amonafide entry in the public domain NCI Dictionary of Cancer Terms
• Clinical trials of amonafide at ClinicalTrials.gov

 This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.